COMMUNIQUÉS West-GlobeNewswire
-
Cortisol Detox App Supports Healthy Fat Loss With Meal Plans and Mindfulness
18/03/2026 -
AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors
18/03/2026 -
OneMedNet and Navidence Announce Strategic Collaboration: Empowering Pharma with Precision Real-World Data Insights
18/03/2026 -
TOMI Environmental Solutions Disrupts Food Safety Sector with 95% Reduction in Sanitation Testing Costs
18/03/2026 -
Prenetics to Participate in the 38th Annual ROTH Conference
18/03/2026 -
Engineered Silkworms Spin Spider Silk as Biotech Firm Targets Commercial Scale
18/03/2026 -
Amphista Therapeutics appoints Louise Modis Ph.D. as CEO and Patrick Kelly M.D. as CMO and provides a business update as the Company prepares to file IND application for AMX-883
18/03/2026 -
Ovid Therapeutics Announces Pricing of $60 Million Private Placement
18/03/2026 -
Greenwich LifeSciences Provides Update on Upcoming AACR Meeting
18/03/2026 -
Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis
18/03/2026 -
XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements
18/03/2026 -
Global survey reveals pet owners lack awareness of parasite risks and seek clearer prevention advice
18/03/2026 -
Peace through well-being: Orion and CMI - Martti Ahtisaari Peace Foundation announce partnership
18/03/2026 -
Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results
18/03/2026 -
BioVersys Reports Corporate Highlights and Financial Results for the Full Year 2025
18/03/2026 -
Ipsen showcases transformative potential of early immuno-oncology pipeline at AACR
18/03/2026 -
Valneva Reports Full Year 2025 Audited Consolidated Financial Results
18/03/2026 -
Valneva publie ses résultats financiers audités et consolidés pour l’exercice 2025
18/03/2026 -
Press Release: Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease
18/03/2026
Pages